International Journal of Nephrology and Renovascular Disease
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
(11494) Total Article Views
Authors: Elizabeth Ripley, Ari Hirsch
Published Date June 2010
Volume 2010:3 Pages 93 - 98
Elizabeth Ripley, Ari Hirsch
Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA
Abstract: Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago.During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowing the progression of diabetic nephropathy, controlling hypertension, and decreasing stroke risk in patients with left ventricular hypertrophy. Although many of the benefits of losartan represent a class effect for ARBs, losartan has pharmacokinetic and pharmacodynamic characteristics and effects that are unique and are not a class effect. For example, a shorter duration of action is seen with this first ARB compared with other more recently approved ARBs. Losartan also has a uricosuric effect not seen in other ARBs and attenuates platelet aggregation, which is not seen or is seen to a lesser extent with the other ARBs. This review presents the physiological effects of losartan on the kidney and discusses relevant clinical outcomes.
Keywords: losartan, chronic kidney disease
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- MLA'14 -
May 16–21, 2014
- Functional evaluation of the urinary tract by duplex Doppler ultrasonography in patients with acute renal colic
- Potential renovascular hypertension, space missions, and the role of magnesium
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?